Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer†

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

(2017) J. E. Pippen et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

(2017) J. O'Shaughnessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

(2011) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?

(2011) A.A. Kotsori et al.   ONCOLOGY

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

(2010) L. Staudacher et al.   ANNALS OF ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer

(2009) G. Frasci et al.   ANNALS OF ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

(2008) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007

(2008) Nicholas Wilcken et al.   EUROPEAN JOURNAL OF CANCER

Basal-Like Breast Cancer: A Critical Review

(2008) Emad A. Rakha et al.   JOURNAL OF CLINICAL ONCOLOGY